End-to-end genotoxicity assessment services for rapid development of CRISPR-based therapies webinar

End-to-end genotoxicity assessment services for rapid development of CRISPR-based therapies webinar
This webinar introduces a comprehensive, scalable framework for off-target risk assessment that integrates orthogonal nomination strategies, including cell‑based (UNCOVERseq), in vitro (CHANGE-seq and ONE-seq), and in silico approaches. Designed to support rapid decision-making, this framework helps researchers and developers prioritize and confirm off-target sites using targeted deep sequencing with our rhAmpSeq™ CRISPR Analysis System.

Published on: November 05, 2025